Cytochrome P450 enzymes: novel options for cancer therapeutics.

The concept of overexpression of individual forms of cytochrome P450 enzymes in tumor cells is now becoming well recognized. Indeed, a growing body of research highlights the overexpression of P450s, particularly CYP1B1, in tumor cells as representing novel targets for anticancer therapy. The purpose of this review is to outline the novel therapeutic options and opportunities arising from both enhanced endogenous expression of cytochrome P450 in tumors and cytochrome P450-mediated gene therapy.

[1]  A. Tomlinson,et al.  The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. , 2003, Blood.

[2]  T. Giordano,et al.  Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Roodi,et al.  Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1. , 2003, Cancer research.

[4]  J. Double,et al.  Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. , 2003, Molecular cancer therapeutics.

[5]  D. Buckley,et al.  Induction of cytochrome P450 3A by paclitaxel in mice: pivotal role of the nuclear xenobiotic receptor, pregnane X receptor. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[6]  E. Sausville,et al.  DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells , 2003, British Journal of Cancer.

[7]  P. Cooper,et al.  Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo , 2003, British Journal of Cancer.

[8]  W. Figg,et al.  2‐Methoxyestradiol, a Promising Anticancer Agent , 2003, Pharmacotherapy.

[9]  S. Kingsman,et al.  Cytochrome P450-based cancer gene therapy: current status , 2002, Expert opinion on biological therapy.

[10]  D. Waxman,et al.  Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. , 2002, Cancer research.

[11]  Danielson Pb,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002 .

[12]  H. Cross,et al.  Transcriptional Inhibition of CYP24 by Genistein , 2002, Annals of the New York Academy of Sciences.

[13]  B. Bournique,et al.  Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[14]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[15]  P. Iversen,et al.  Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[16]  J. Gordan,et al.  Universal tumor antigens as targets for immunotherapy. , 2002, Cytotherapy.

[17]  G. Murray,et al.  Tumour cytochrome P450 and drug activation. , 2002, Current pharmaceutical design.

[18]  V. Njar.  Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. , 2002, Mini reviews in medicinal chemistry.

[19]  A. Tari,et al.  all‐trans‐Retinoic acid‐induced expression and regulation of retinoic acid 4‐hydroxylase (CYP26) in human promyelocytic leukemia , 2002, American journal of hematology.

[20]  A. Birnbaum,et al.  Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA , 2002, Cancer Chemotherapy and Pharmacology.

[21]  M. Lang,et al.  CYP2A6/2A7 and CYP2E1 expression in human oesophageal mucosa: regional and inter-individual variation in expression and relevance to nitrosamine metabolism. , 2002, Carcinogenesis.

[22]  P. Farmer,et al.  The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 , 2002, British Journal of Cancer.

[23]  L. H. Patterson.  BIOREDUCTIVELY ACTIVATED ANTITUMOR N-OXIDES: THE CASE OF AQ4N, A UNIQUE APPROACH TO HYPOXIA-ACTIVATED CANCER CHEMOTHERAPY , 2002, Drug metabolism reviews.

[24]  E. Frei,et al.  The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. , 2001, Biochemical pharmacology.

[25]  S. Hunt.  Technology evaluation: MetXia-P450, Oxford Biomedica. , 2001, Current opinion in molecular therapeutics.

[26]  H. Mohrenweiser,et al.  Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. , 2001, The Journal of pharmacology and experimental therapeutics.

[27]  J. Memelink,et al.  Geraniol 10‐hydroxylase1, a cytochrome P450 enzyme involved in terpenoid indole alkaloid biosynthesis , 2001, FEBS letters.

[28]  Robert M. Williams,et al.  Taxol biosynthesis: Taxane 13α-hydroxylase is a cytochrome P450-dependent monooxygenase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Desai,et al.  Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel , 2001, Cancer Chemotherapy and Pharmacology.

[30]  G. Schwartsmann,et al.  Natural products in anticancer therapy. , 2001, Current opinion in pharmacology.

[31]  H. Cross,et al.  25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. , 2001, Biochemical and biophysical research communications.

[32]  H. McLeod,et al.  Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. , 2001, Biochemical pharmacology.

[33]  H. McLeod,et al.  Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer , 2001, British Journal of Cancer.

[34]  N. Kohno,et al.  Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer , 2001, Cancer Chemotherapy and Pharmacology.

[35]  Robert M. Long,et al.  Taxol biosynthesis: differential transformations of taxadien-5 alpha-ol and its acetate ester by cytochrome P450 hydroxylases from Taxus suspension cells. , 2001, Archives of biochemistry and biophysics.

[36]  M. Holick,et al.  25-hydroxyvitamin D-1α-hydroxylase in normal and malignant colon tissue , 2001, The Lancet.

[37]  M. Löhr,et al.  Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma , 2001, The Lancet.

[38]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[39]  H. McLeod,et al.  Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? , 2001, The Journal of pharmacology and experimental therapeutics.

[40]  J. Skouv,et al.  Increased expression of cytochrome p450 1A1 and 1B1 genes in anti‐estrogen–resistant human breast cancer cell lines , 2000, International journal of cancer.

[41]  S. McKeown,et al.  AQ4N: a new approach to hypoxia-activated cancer chemotherapy , 2000, British Journal of Cancer.

[42]  S. Irmler,et al.  Indole alkaloid biosynthesis in Catharanthus roseus: new enzyme activities and identification of cytochrome P450 CYP72A1 as secologanin synthase. , 2000, The Plant journal : for cell and molecular biology.

[43]  G I Murray,et al.  The role of cytochrome P450 in tumour development and progression and its potential in therapy , 2000, The Journal of pathology.

[44]  D. Ong,et al.  Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells , 2000 .

[45]  P. Souček,et al.  Cytotoxicity of cyclophosphamide, paclitaxel, and docetaxel for tumor cell lines in vitro: effects of concentration, time and cytochrome P450-catalyzed metabolism , 2000, Archives of Toxicology.

[46]  H. Kobayashi,et al.  CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[47]  W. Denny.  The role of hypoxia-activated prodrugs in cancer therapy. , 2000, The Lancet. Oncology.

[48]  C. Wolf,et al.  Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. , 2000, The Journal of pharmacology and experimental therapeutics.

[49]  W. Kuo,et al.  Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene , 2000, Nature Genetics.

[50]  D. Waxman,et al.  Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. , 2000, Biochemical pharmacology.

[51]  A. Harris,et al.  The macrophage – a novel system to deliver gene therapy to pathological hypoxia , 2000, Gene Therapy.

[52]  M. Symons,et al.  Effects of AQ4N and its reduction product on radiation-mediated DNA strand breakage. , 1999, Chemico-biological interactions.

[53]  G. Murray,et al.  Immunohistochemical Localization of Cytochrome P450 CYP1B1 in Breast Cancer with Monoclonal Antibodies Specific for CYP1B1 , 1999, Journal of Histochemistry and Cytochemistry.

[54]  M. Ingelman-Sundberg,et al.  Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. , 1999, Trends in pharmacological sciences.

[55]  V. Colantuoni,et al.  Changes in tissue transglutaminase activity and expression during retinoic acid-induced growth arrest and apoptosis in primary cultures of human epithelial prostate cells. , 1999, The Journal of clinical endocrinology and metabolism.

[56]  J. Schellens,et al.  In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. , 1998, Cancer treatment reviews.

[57]  K. Chiba,et al.  A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. , 1998, The Journal of pharmacology and experimental therapeutics.

[58]  M. Ratain,et al.  Pharmacogenetics and cancer chemotherapy. , 1998, European journal of cancer.

[59]  S. Wrighton,et al.  Induction of cytochrome P4503A by taxol in primary cultures of human hepatocytes. , 1998, Archives of biochemistry and biophysics.

[60]  E. Bowman,et al.  Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. , 1998, European journal of cancer.

[61]  G. Vassal,et al.  Preclinical development of camptothecin derivatives and clinical trials in pediatric oncology. , 1998, Biochimie.

[62]  J A McKay,et al.  Tumor-specific expression of cytochrome P450 CYP1B1. , 1997, Cancer research.

[63]  P. Wen,et al.  Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. , 1996, Gene therapy.

[64]  G. de Sousa,et al.  Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. , 1996, Cancer research.

[65]  D. Waxman,et al.  Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. , 1996, Cancer research.

[66]  D. Hirst,et al.  DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. , 1996, British Journal of Cancer.

[67]  M. Eichelbaum,et al.  The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. , 1995, British journal of clinical pharmacology.

[68]  W. F. Greenlee,et al.  Expression of cytochrome P450 CYP1B1 in breast cancer , 1995, FEBS letters.

[69]  S. McKeown,et al.  AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. , 1995, British Journal of Cancer.

[70]  M. Relling,et al.  Clinical Pharmacokinetics of Paclitaxel , 1994, Clinical pharmacokinetics.

[71]  X. Breakefield,et al.  Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. , 1994, Human gene therapy.

[72]  R. Weaver,et al.  Cytochrome P450 expression in oesophageal cancer. , 1994, Gut.

[73]  M. Relling,et al.  O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. , 1994, Molecular pharmacology.

[74]  R. Weaver,et al.  Cytochrome P450 expression is a common molecular event in soft tissue sarcomas , 1993, The Journal of pathology.

[75]  R. Estabrook,et al.  Cytochrome P450 and the arachidonate cascade 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[76]  R. Weaver,et al.  Expression of cytochrome P450IA in breast cancer. , 1991, British Journal of Cancer.

[77]  E. Kallay,et al.  Regulation of extrarenal vitamin D metabolism as a tool for colon and prostate cancer prevention. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[78]  N. Roodi,et al.  Methoxyestrogens Exert Feedback Inhibition on Cytochrome P 450 1 A 1 and 1 B 11 , 2003 .

[79]  Tracy Robson,et al.  Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N , 2003, Cancer Gene Therapy.

[80]  P. Danielson,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002, Current drug metabolism.

[81]  S. Imaoka,et al.  Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. , 2002, The Journal of pharmacology and experimental therapeutics.

[82]  A. Conley,et al.  Mammalian aromatases. , 2001, Reproduction.

[83]  W. F. Greenlee,et al.  Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. , 2001, Annual review of pharmacology and toxicology.

[84]  M. Sovák.  Grape Extract, Resveratrol, and Its Analogs: A Review. , 2001, Journal of medicinal food.

[85]  F. Gonzalez,et al.  Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. , 1994, Drug metabolism reviews.

[86]  T. Stamey,et al.  Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells , 1993, The Prostate.